A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Zentiva®Drug: Placebo
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT05278104
- Locations
- 🇩🇪
Universitätsklinikum Aachen, AöR, Aachen, Germany
🇩🇪Rheinhessen-Fachklinik Alzey, Alzey, Germany
🇩🇪Universitätsklinikum Bonn AöR, Bonn, Germany
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1200
- Registration Number
- NCT05262764
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT05262751
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT05258110
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Other: Investigator´s Choice Chemotherapy
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT05249426
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
🇵🇱Mandziuk Slawomir Specialist Medical Practice, Lublin, Poland
🇷🇴"Prof. Dr. Alexandru Trestioreanu" Oncology Institut, Bucharest, Romania
A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 322
- Registration Number
- NCT05238675
- Locations
- 🇳🇱
Amsterdam UMC, location VUMC, Amsterdam, Netherlands
🇪🇸Hospital de Mérida, Mérida, Spain
🇺🇸Malcom Randall VA Medical Center, Gainesville, Florida, United States
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT05239039
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇨🇳Beijing Friendship Hospital, Beijing, China
🇨🇳West China Hospital, Chengdu, China
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 610
- Registration Number
- NCT05236673
- Locations
- 🇰🇷
Hallym University Medical Center, Anyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 401
- Registration Number
- NCT05218499
- Locations
- 🇮🇹
A.O. Univ. Policlinico Giaccone, Palermo, Italy
🇩🇪Helios Klinikum Berlin-Buch, Berlin, Germany
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 67
- Registration Number
- NCT05213624
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Salford Royal, Salford, United Kingdom
🇮🇹Policlinico S. Orsola-Malpighi, Bologna, Italy